SEC Form 4 · accession 0001209191-19-012970
Deciphera Pharmaceuticals, Inc. · DCPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel Lee Flynn
Officer — Chief Scientific Officer
Period of report
Feb 21, 2019
Accepted (ET)
Feb 25, 2019 · 4:16 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001654151
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 21, 2019 | M | 24,500 | $3.95 | A | 24,500 | D | |
| Common Stock | holding | — | — | — | 91,779 | I | By Daniel L.Flynn Irrevocable Trust | |
| Common Stock | holding | — | — | — | 55,270 | I | By Biochenomix, LLC |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $3.95 | Feb 21, 2019 | M | 24,500 | D | — | Sep 26, 2026 | Common Stock | 24,500 | 15,050 | D |
Explanation of responses
- F1This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 48 equal monthly installments at the end of each month following the vesting commencement date of July 1, 2016, subject to continued service through such dates.